专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022269081A1 BACILLUS LICHENIFORMIS HOST CELL FOR PRODUCTION OF A COMPOUND OF INTEREST WITH INCREASED PURITY 审中-公开
公开(公告)号：WO2022269081A1
公开(公告)日：2022-12-29
申请号：PCT/EP2022/067439
申请日：2022-06-24
申请人： BASF SE
发明人： FELLE, Max Fabian , APPELBAUM, Mathis , SAUER, Christopher , JENEWEIN, Stefan
IPC分类号： C07K14/32 , C12N15/67 , C12N15/75
摘要： The present invention relates to a Bacillus licheniformis host cell for production of biological compounds with increased purity. Specifically, the invention relates to a Bacillus licheniformis host with one or more genetic modifications selected from a) a genetic modification causing compared to an unmodified control cell an increased expression of at least one of the genes selected from the group consisting of degQ, degll, degS, degR, and phrG, b) a genetic modification causing compared to an unmodified control cell an increased autophosphorylation activity of the DegS protein, and c) a genetic modification causing compared to an unmodified control cell a reduced phosphatase activity of the DegS protein. The present invention further relates to a method for production of at least one compound of interest with increased purity based on cultivating the bacterial host cell of the present invention.

2. 发明申请

WO2021122921A1 USE OF COPS3 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION 审中-公开
公开(公告)号：WO2021122921A1
公开(公告)日：2021-06-24
申请号：PCT/EP2020/086676
申请日：2020-12-17
申请人： F. HOFFMANN-LA ROCHE AG , HOFFMANN-LA ROCHE INC.
发明人： PEDERSEN, Lykke , LUANGSAY, Souphalone , WALTHER, Johanna Marie , MUELLER-BRECKENRIDGE, Alan James
IPC分类号： C12N15/113 , C12N15/1135 , C12N15/1137 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/3521 , C12N2310/3525 , C12N2310/3533 , C12N2310/531 , C12Y207/01037
摘要： The present invention relates to a COPS3 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of COPS3 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to COPS3 and capable of reducing the level of a COPS3 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.

3. 发明申请

WO2020165409A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS COMPRISING AN AMYLASE CLEAVABLE LINKER 审中-公开
公开(公告)号：WO2020165409A1
公开(公告)日：2020-08-20
申请号：PCT/EP2020/053891
申请日：2020-02-14
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM , RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
发明人： EDER, Matthias , KOPKA, Klaus , SCHÄFER, Martin , BAUDER-WUEST, Ulrike , HABERKORN, Uwe , KLIEM, Hans-Christian , MIER, Walter , LINDNER, Thomas
IPC分类号： A61K51/04 , A61P35/00
摘要： In particular, the present invention relates to a PSMA binding ligand comprising an oligosaccharide building block which comprises a bond being cleavable by alpha-amylase. Typically, this PSMA binding ligand further comprises a PSMA binding motif Q and a chelator residue A, wherein the PSMA binding motif Q and the chelator residue A are preferably linked via at least one linker A-L AQ -Q comprising the oligosaccharide building block, the PSMA binding ligand thus preferably having the structure (I) or a pharmaceutically acceptable salt or solvate thereof

4. 发明申请

WO2020039085A1 CIRCULATING FGFBP-1 (FIBROBLAST GROWTH FACTOR-BINDING PROTEIN 1) IN THE ASSESSMENT OF ATRIAL FIBRILLATION AND FOR THE PREDICTION OF STROKE 审中-公开
公开(公告)号：WO2020039085A1
公开(公告)日：2020-02-27
申请号：PCT/EP2019/072624
申请日：2019-08-23
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , MAASTRICHT UNIVERSITY MEDICAL CENTER , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： DIETRICH, Manuel , KASTNER, Peter , ZIEGLER, André , WIENHUES-THELEN, Ursula-Henrike , ROLNY, Vinzent , SCHOTTEN, Ulrich
IPC分类号： G01N33/68
摘要： The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of FGFBP-1 in a sample from the subject, and comparing the amount of FGFBP-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of FGFBP-1.

5. 发明申请

WO2020035605A1 CIRCULATING BMP10 (BONE MORPHOGENIC PROTEIN 10) IN THE ASSESSMENT OF ATRIAL FIBRILLATION 审中-公开
公开(公告)号：WO2020035605A1
公开(公告)日：2020-02-20
申请号：PCT/EP2019/072042
申请日：2019-08-16
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , MAASTRICHT UNIVERSITY MEDICAL CENTER , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： KARL, Johann , KASTNER, Peter , WIENHUES-THELEN, Ursula-Henrike , DIETRICH, Manuel , ZIEGLER, André , SCHOTTEN, Uli
IPC分类号： G01N33/68
摘要： The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP 10 in a sample from the subject, and comparing the amount of BMP 10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP 10-type peptide in a sample from a subject.

6. 发明申请

WO2017021303A1 METHOD FOR PROVIDING A SUCCINIC ACID SOLUTION 审中-公开
标题翻译：提供酸性溶液的方法
公开(公告)号：WO2017021303A1
公开(公告)日：2017-02-09
申请号：PCT/EP2016/068169
申请日：2016-07-29
申请人： PURAC BIOCHEM B.V.
发明人： JANSEN, Peter Paul , VAN BREUGEL, Jan , VAN BOCHOVE, Gerard Hendrik , VIDAL LANCIS, José María , ÐEKIC ŽIVKOVIC, Tanja
IPC分类号： C01B7/03 , C01F5/10 , C01F5/30 , C07C51/02 , C07C51/43
CPC分类号： C01B7/035 , C01F5/10 , C01F5/30 , C07C51/02 , C07C51/43 , C07C55/10
摘要： The invention pertains to a method for providing a succinic acid solution, comprising the steps of - providing a first magnesium succinate containing medium with a magnesium succinate concentration of 18-23 wt.% to a first acidification reactor where it is contacted with hydrogen chloride to form a solution of succinic acid, magnesium chloride and hydrogen chloride, - providing a second magnesium succinate containing medium with a magnesium succinate concentration of 25-50 wt.%, and contacting it in a second acidification reactor with the solution of succinic acid, magnesium chloride and hydrogen chloride withdrawn from the first acidification reactor, to form an aqueous mixture comprising magnesium chloride and succinic acid with a succinic acid concentration of at least 18 wt.%. The method according to the invention makes it possible to obtain a solution comprising succinic acid and magnesium 20 chloride with an increased succinic acid concentration.
摘要翻译：本发明涉及一种提供琥珀酸溶液的方法，包括以下步骤：向第一酸化反应器提供含有琥珀酸琥珀酸钠浓度为18-23重量％的第一琥珀酸琥珀酸盐，其中其与氯化氢接触，形成琥珀酸，氯化镁和氯化氢的溶液， - 提供含有琥珀酸镁浓度为25-50重量％的第二个琥珀酸琥珀酸盐，并在第二酸化反应器中与琥珀酸，镁从第一酸化反应器中取出的氯化物和氯化氢，以形成琥珀酸浓度至少为18重量％的含有氯化镁和琥珀酸的含水混合物。根据本发明的方法使得可以获得包含琥珀酸和二氯化镁的琥珀酸浓度增加的溶液。

7. 发明申请

WO2016097116A1 METHODS FOR REDUCING INTERFERENCES 审中-公开
标题翻译：减少干扰的方法
公开(公告)号：WO2016097116A1
公开(公告)日：2016-06-23
申请号：PCT/EP2015/080176
申请日：2015-12-17
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： UPMEIER, Barbara , ZARNT, Toralf , POLZ, Johannes
IPC分类号： G01N33/53 , G01N33/543
CPC分类号： G01N33/54393 , G01N33/54306 , G01N33/6854 , G01N2800/26
摘要： The present invention relates to a method for determining an analyte in a sample suspected to comprise said analyte, comprising a) contacting with said sample at least a first and a second capture compound for said analyte, wherein said first and second capture compounds are non- identical capture compounds, and wherein said capture compounds compete in binding to said analyte; b) contacting said capture compounds contacted with said sample with a specifier, wherein said specifier competes in binding to said capture compounds with said analyte; c) determining the amount of complexes comprising said specifier and a capture compound; and d) determining said analyte in a sample based on the result of step c). The present invention further relates to a method for improving the specificity of an indirect immunoassay for determining an analyte, comprising replacing at least 10% of a capture compound by a non-identical capture compound; wherein the capture compound replaced competes in binding to said analyte with the capture compound introduced. The present invention further relates to kits, devices, and uses related to the aforementioned methods.
摘要翻译：本发明涉及一种用于确定怀疑含有所述分析物的样品中的分析物的方法，包括a）与所述样品至少接触所述分析物的第一和第二捕获化合物，其中所述第一和第二捕获化合物是非 - 相同的捕获化合物，并且其中所述捕获化合物竞争结合所述分析物; b）使与所述样品接触的所述捕获化合物与指定剂接触，其中所述说明符与所述分析物竞争结合所述捕获化合物; c）确定包含所述说明符和捕获化合物的复合物的量; 以及d）基于步骤c）的结果确定样品中的所述分析物。本发明还涉及一种用于改进用于确定分析物的间接免疫测定的特异性的方法，其包括用非相同捕获化合物代替至少10％的捕获化合物; 其中捕获化合物用引入的捕获化合物取代与所述分析物结合的竞争。本发明还涉及与上述方法相关的试剂盒，装置和用途。

8. 发明申请

WO2016079310A1 METHODS FOR THE DETERMINATION OF THE BIOLOGICAL ACTIVITIES OF NEUROTOXIN POLYPEPTIDES 审中-公开
标题翻译：测定神经毒素多糖生物活性的方法
公开(公告)号：WO2016079310A1
公开(公告)日：2016-05-26
申请号：PCT/EP2015/077245
申请日：2015-11-20
申请人： MERZ PHARMA GMBH & CO. KGAA
发明人： EISELE, Karl-Heinz
IPC分类号： G01N33/569 , C07K14/00
CPC分类号： G01N33/6809 , C07K14/70571 , C07K2319/61 , G01N33/56911
摘要： The present invention pertains to a method for determining the biological activity of a neurotoxin, the method comprising the steps of: (a) expressing a fusion protein comprising (i) an anchor protein, (ii) a reporter protein and (iii) a neurotoxin cleavage site intervening the anchor protein and the reporter protein, in neurotoxin-sensitive cells; (b) incubating the neurotoxin-sensitive cells of (a) with a neurotoxin and cultivating the cells under conditions which allow the neurotoxin to exert its biological activity; (c) permeabilizing the neurotoxin-sensitive cells of (b) under conditions which allow the release of the reporter protein but not the release of the anchor protein from the permeabilized neurotoxin-sensitive cells; and (d) quantifying the activity of the reporter protein released from the cells, thereby determining the biological activity of the neurotoxin. In addition, the invention relates to a fusion protein comprising (i) an anchor protein, (ii) a reporter protein, and (iii) a neurotoxin cleavage site intervening the anchor protein and the reporter protein, for determining the biological activity of a neurotoxin, in neurotoxin-sensitive cells. Further encompassed by the present invention is a kit comprising the fusion protein of the invention. Finally, the invention pertains to the use of a fusion protein of the invention for determining the biological activity of a neurotoxin, in neurotoxin-sensitive cells.
摘要翻译：本发明涉及一种用于测定神经毒素生物活性的方法，所述方法包括以下步骤：（a）表达融合蛋白，其包含（i）锚蛋白，（ii）报道蛋白和（iii）神经毒素在神经毒素敏感细胞中插入锚蛋白和报告蛋白的切割位点; （b）将（a）的神经毒素敏感细胞与神经毒素孵育并在允许神经毒素发挥其生物活性的条件下培养细胞; （c）在允许释放报告蛋白但不从透化的神经毒素敏感细胞释放锚蛋白的条件下使（b）的神经毒素敏感细胞透化; 和（d）定量从细胞释放的报道蛋白的活性，从而确定神经毒素的生物活性。此外，本发明涉及融合蛋白，其包含（i）锚蛋白，（ii）报道蛋白，和（iii）插入锚蛋白和报道蛋白的神经毒素切割位点，用于确定神经毒素的生物学活性，在神经毒素敏感细胞。本发明进一步包括的是包含本发明的融合蛋白的试剂盒。最后，本发明涉及本发明的融合蛋白在神经毒素敏感细胞中用于测定神经毒素的生物学活性的用途。

9. 发明申请

WO2016066698A1 BIOMARKERS FOR RISK PREDICTION OF MORTALITY 审中-公开
标题翻译：风险预测的生物标志物
公开(公告)号：WO2016066698A1
公开(公告)日：2016-05-06
申请号：PCT/EP2015/075012
申请日：2015-10-28
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： LATINI, Roberto , MASSON, Serge , BLOCK, Dirk , ZAUGG, Christian , DIETERLE, Thomas , KAISER, Edelgard , KARL, Johann , ROLNY, Vinzent , WIENHUES-THELEN, Ursula-Henrike
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4703 , G01N2333/4712 , G01N2333/4745 , G01N2333/475 , G01N2333/495 , G01N2333/50 , G01N2333/515 , G01N2333/58 , G01N2333/70525 , G01N2800/325
摘要： The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/ or death. The method is based on the determination of at least one bio marker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
摘要翻译：本发明涉及一种用于预测快速进展为慢性心力衰竭和/或由于慢性心力衰竭和/或死亡引起的住院治疗的受试者的风险的方法。该方法基于至少一种选自由BNP型肽，IGFBP7（IGF结合蛋白7），心肌肌钙蛋白，可溶性ST2（sST2），FGF-23（成纤维细胞生长因子 23）和生长分化因子15（GDF-15）。该方法还可以包括（i）异常中壁部分缩短或（ii）左心室肥大的存在或不存在的评估。本发明进一步设想的是适用于实施本发明的设备。

10. 发明申请

WO2015169920A1 GENETICALLY MODIFIED MICROORGANISM FOR IMPROVED PRODUCTION OF FINE CHEMICALS ON SUCROSE 审中-公开
标题翻译：用于改善生产精细化学品的遗传改良微生物
公开(公告)号：WO2015169920A1
公开(公告)日：2015-11-12
申请号：PCT/EP2015/060102
申请日：2015-05-07
申请人： BASF SE
发明人： KRAWCZYK, Joanna Martyna , HAEFNER, Stefan , SCHROEDER, Hartwig , ZELDER, Oskar
IPC分类号： C12P7/46 , C12R1/01 , C12N9/12
CPC分类号： C12N15/102 , C07K14/195 , C12N15/74 , C12N2510/02 , C12P7/46 , C12Y207/11
摘要： The present invention relates to a modified microorganism having, compared to its wildtype, -a reduced activity of an enzyme encoded by the ptsA -gene, -a reduced activity of an enzyme encoded by the ptsH -gene or -a reduced activity of an enzyme encoded by the ptsA -gene and a reduced activity of an enzyme encoded by the ptsH -gene, wherein the wildtype from which the modified microorganism has been derived belongs to the family of Pasteurellaceae . The present invention also relates to a method for producing succinic acid and to the use of modified microorganisms.
摘要翻译：本发明涉及一种修饰的微生物，其与野生型相比具有降低的由ptsA基因编码的酶的活性， - 由ptsH基因编码的酶的活性降低或 - 酶活性降低由ptsA基因编码并且由ptsH基因编码的酶的活性降低，其中已经衍生了经修饰的微生物的野生型属于巴氏杆菌科。本发明还涉及生产琥珀酸的方法和使用改性微生物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式